SEARCH

SEARCH BY CITATION

References

  • Barnes AG, Cerovic V, Hobson PS & Klavinskis LS (2007) Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur J Immunol 37: 15381547.
  • Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN & Kelly CP (2008) A mouse model of Clostridium difficile-associated disease. Gastroenterology 135: 19841992.
  • Dawson LF, Valiente E, Faulds-Pain A, Donahue EH & Wren BW (2012) Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS One 7: e50527.
  • Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren BW, Fairweather NF, Dougan G & Lawley TD (2012) The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 80: 27042711.
  • Gough E, Shaikh H & Manges AR (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53: 9941002.
  • Harwood CR & Cutting SM (1990) Molecular Biological Methods for Bacillus. John Wiley & Sons Ltd, Chichester, UK.
  • Hoa TT, Duc LH, Isticato R, Baccigalupi L, Ricca E, Van PH & Cutting SM (2001) Fate and dissemination of Bacillus subtilis spores in a murine model. Appl Environ Microbiol 67: 38193823.
  • Hong HA, To E, Fakhry S, Baccigalupi L, Ricca E & Cutting SM (2009) Defining the natural habitat of Bacillus spore-formers. Res Microbiol 160: 375379.
  • Hosoi T & Kiuchi K (2004) Production and Probiotic Effects of Natto. (Ricca E, Henriques AO & Cutting SM, eds), pp. 143154. Horizon Bioscience, Wymondham, UK.
  • HPA (2009) Clostridium difficile Infection: How to Deal with the Problem. pp. 130. Health Protection Agency, London, UK.
  • Huang JM, La Ragione RM, Nunez A & Cutting SM (2008a) Immunostimulatory activity of Bacillus spores. FEMS Immunol Med Microbiol 53: 195203.
  • Huang JM, La Ragione RM, Cooley WA, Todryk S & Cutting SM (2008b) Cytoplasmic delivery of antigens, by Bacillus subtilis enhances Th1 responses. Vaccine 26: 60436052.
  • Huang JM, Hong HA, Van Tong H, Hoang TH, Brisson A & Cutting SM (2010) Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 28: 10211030.
  • Jarchum I, Liu M, Lipuma L & Pamer EG (2011) Toll-like receptor-5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 79: 14981503.
  • Lawley TD, Clare S, Walker AW et al. (2009) Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77: 36613669.
  • Lawley TD, Clare S, Walker AW et al. (2012) Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8: e1002995.
  • Liu Y, Wang Y, Yamakuchi M, Isowaki S, Nagata E, Kanmura Y, Kitajima I & Maruyama I (2001) Upregulation of toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-kappa b activation. Infect Immun 69: 27882796.
  • MacConnachie AA, Fox R, Kennedy DR & Seaton RA (2009) Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 102: 781784.
  • Mauriello EM, Cangiano G, Maurano F, Saggese V, De Felice M, Rossi M & Ricca E (2007) Germination-independent induction of cellular immune response by Bacillus subtilis spores displaying the C fragment of the tetanus toxin. Vaccine 25: 788793.
  • Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF & Cutting SM (2011) Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79: 22952302.
  • Permpoonpattana P, Hong HA, Khaneja R & Cutting SM (2012) Evaluation of Bacillus subtilis strains as probiotics and their potential as a food ingredient. Benef Microbes 3: 127135.
  • Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K & Allen-Vercoe E (2013) Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 1: 3.
  • Pochapin M (2000) The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 95: S11S13.
  • Rouphael NG, O'Donnell JA, Bhatnagar J et al. (2008) Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol 198: 635 e631e636.
  • Rupnik M, Wilcox MH & Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7: 526536.
  • Schyns G, Serra CR, Lapointe T, Pereira-Leal JB, Potot S, Fickers P, Perkins JB, Wyss M & Henriques AO (2014) Genome of a gut strain of Bacillus subtilis. Genome Announc 2: in press.
  • Surawicz CM, McFarland LV, Greenberg RN et al. (2000) The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31: 10121017.
  • Tam NK, Uyen NQ, Hong HA, le Duc H, Hoa TT, Serra CR, Henriques AO & Cutting SM (2006) The intestinal life cycle of Bacillus subtilis and close relatives. J Bacteriol 188: 26922700.
  • Wilcox MH, Mooney L, Bendall R, Settle CD & Fawley WN (2008) A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 62: 388396.
  • Wullt M, Hagslatt ML & Odenholt I (2003) Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35: 365367.
  • Youngman P, Perkins J & Losick R (1984) Construction of a cloning site near one end of Tn917 into which foreign DNA may be inserted without affecting transposition in Bacillus subtilis or expression of the transposon-borne erm gene. Plasmid 12: 19.